explore -WSS

explore

author：entertainment 2025-09-28 21:06:11 - browse：4512

ADAM FEUERSTEIN/STAT

CHICAGO — Corbus Pharmaceuticals is the second best-performing biotech stock this year, thanks to investor interest in an antibody-drug conjugate candidate, or ADC, called CRB-701 with the potential to be better tolerated than Padcev, an ADC treatment bladder cancer that Pfizer acquired as part of its $43 billion Seagen deal.

On Saturday, Corbus updated results from an early, dose-finding study of CRB-701, showing an overall response rate of 28% from 25 evaluable patients. Closer attention is being paid to the subset of 15 patients treated at three therapeutically active doses, where the overall response rate (all partial tumor shrinkage) was 40%. All of the responses were seen in bladder cancer (where Padcev is approved) and in cervical cancer.

The data, from a study conducted in China, were presented in a poster session at the annual meeting of the American Society of Clinical Oncology.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Harvard's Jason Buenrostro wins MacArthur grant for genetics work

WSS

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

'Insanity': 4th of July mass shootings across US kill 13, injure more than 80

CZI to create biohub to build anti

Results on Novartis prostate cancer therapy could expand its use

China dismisses criticism of top diplomat's comments appearing to push for race

China dismisses criticism of top diplomat's comments appearing to push for race

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Drug repurposing or repositioning? The language matters

STAT Readout Newsletter: Biotech news today

Moonlake's readout produced a cash windfall. Risks remain

ADCs take center stage as promising cancer treatments

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Accuser says Kevin Spacey grope wasn't a caress: ‘It was like a cobra ... angry’

BioMarin wins approval for gene therapy to treat hemophilia A

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

How one medical school became remarkably diverse

Roche drug slashes death risk in early

focus

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Gov. Ron DeSantis' push for 'civics' education: What does it look like?

Supreme Court shows surprising restraint in chaotic year of crises: ANALYSIS

The problems with dementia villages

Man pleads guilty to raping Ohio girl who ended up traveling across state lines for abortion

Pope Francis asks Church to identify 21st

Wikipedia

leisure time

hotspot

Wikipedia